





ENTREPRENEUR SPOTLIGHT

POWERED BY HATCH BIOFUND

JULY 18, 2024 3-5 p.m. EDT

The winning company will receive an investment of 250K!



Est. by the Hepatitis B Foundation



PROGRAM

Welcome & Intro: Lou Kassa, MPA, CEO, Hepatitis B Foundation, Pennsylvania Biotechnology Center (PABC) & Blumberg Institute

VIP Remarks

Bob Harvie, Bucks Co. Commissioner Sen. Steve Santarsiero

Emcee: Lorenzo Pellegrini, PhD, Managing Partner, Hatch Biofund

Introduction of Panel:

Eric Heil, MBA, Medical Excellence Capital Rick Jones, MD, MBA, BioAdvance Kathie Jordan, PhD, Ben Franklin Technologies Jim Nelson, MBA, Venable LLP

Company Presentations

Eliksa Therapeutics, Armen Karamanian, MD, PhD ThirdLaw Molecular, Christian Schafmeister, PhD HULA Therapeutics, Steve Gelone, PharmD

Networking Hour

Please complete your voting within 5 minutes.
The **winner** will be announced during the networking hour.






Discovery - Safety Assessment - Metabolism Integrated IND programs - Bioanalysis

Plan your next nonclinical study with us for an IND-/CTA-enabling package to get you from research to clinical trials faster



www.labcorp.com/biopharma/nonclinical-studies





Pennsylvania knowledge & connections – 1000 attorneys in more than 70 practice areas coast to coast.

That's the Fox Rothschild Advantage.





FEATURED COMPANY



Based at the PABC in Doylestown, Eliksa Therapeutics is developing secretome-based therapies to address significant unmet needs in ocular, cardiovascular and osteoarthritic conditions. These therapies have emerged as a promising approach to overcome the traditional limitations associated with cell-based treatments. Eliksa's lead product candidate, ELK-003, is being developed to treat ocular manifestations of Epidermolysis Bullosa and entered clinical trials in 2024.



ARMEN KARAMANIAN, MD, PHD
CO-FOUNDER & CEO

FEATURED COMPANY



ThirdLaw Molecular, based in Blue Bell, Pa., is developing technologies from Temple University. The company is working to advance its Spiroligomer™ molecules as an innovative, patent-protected, new class of targeted medicines. The company's mission is to create a revolutionary category of molecules that transform how diseases are treated more safely and effectively.



CHRISTIAN SCHAFMEISTER, PHD

PRESIDENT, CSO, FOUNDER, PROFESSOR OF CHEMISTRY



Give your business a boost

univest.net | 877.723.5571



See what's possible.





THIS EVENT IS POWERED BY



Hatch Biofund is a life sciences venture capital firm headquartered in the Philadelphia region and affiliated with the Pennsylvania Biotechnology Center in Doylestown, Pa. Hatch was formed to provide early-stage capital to promising local life science companies, along with access to deep industry expertise and physical platforms to help them realize their missions.



LORENZO PELLEGRINI, PHD

MANAGING PARTNER

Lorenzo has overall responsibilities for Hatch's investing and operating activities. He is a scientist, investor and entrepreneur with 30 years of experience in the life sciences and is committed to translating scientific discoveries into products that make a difference in patients' lives.

Lorenzo was the founder or co-founder of six biotech companies, as either sole founder or venture capital equity co-founder and manager. Prior to joining Hatch, he was the Founder of Palladio Biosciences, a drug development company developing innovative drugs for the treatment of rare kidney diseases. Serving as Palladio's first CEO, he raised \$20 million in venture capital financing and advanced the company's lead drug from IND to Phase 2 studies.



HULA Therapeutics is dedicated to bringing safer and more efficacious therapies for children and adults with solid tumors.

Leveraging a novel target discovery engine developed at Children's Hospital of Philadelphia, the company aims to be in the clinic in late 2024 with a CAR-T cell therapy for neuroblastoma. HULA Therapeutics also is working on programs for sarcoma, medulloblastoma and gliomas.



STEVE GELONE, PHARMD
PRESIDENT & CFO

PANELISTS



KATHIE JORDAN, PHD

MANAGING DIRECTOR,
BEN FRANKLIN TECHNOLOGY PARTNERS



JAMES E. NELSON, MBA

PARTNER, VENABLE LLP

PANELISTS



ERIC HEIL, MBA

MANAGING PARTNER,

MEDICAL EXCELLENCE CAPITAL



FREDERICK JONES, MD, MBA
PARTNER, BIOADVANCE